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Abstract
Background: Neural recognition molecule L1CAM, which is a key protein involved in early nervous system
development, is known to be abnormally expressed and shed in several types of cancers where it participates in
metastasis and progression. The distinction of L1CAM presence in cancerous vs. normal tissues has suggested it to
be a new target for cancer treatment. Our current study focused on the potential role of soluble L1CAM in breast
cancer cell adhesion to extracellular matrix proteins, migration, and invasion.
Results: We found L1 expression levels were correlated with breast cancer stage of progression in established data
sets of clinical samples, and also were high in more metastatic breast cancer cell lines MDA-MB-231 and MDA-MB-
435, but low in less migratory MDA-MB-468 cells. Proteolysis of L1 into its soluble form (sL1) was detected in cell
culture medium from all three above cell lines, and can be induced by PMA activation. Over-expression of the L1
ectodomain in MDA-MB-468 cells by using a lentiviral vector greatly increased the amount of sL1 released by those
cells. Concomitantly, cell adhesion to extracellular matrix and cell transmigration ability were significantly
promoted, while cell invasion ability through Matrigel™ remained unaffected. On the other hand, attenuating L1
expression in MDA-MB-231 cells by using a shRNA lentiviral vector resulted in reduced cell-matrix adhesion and
transmigration. Similar effects were also shown by monoclonal antibody blocking of the L1 extracellular region.
Moreover, sL1 in conditioned cell culture medium induced a directional migration of MDA-MB-468 cells, which
could be neutralized by antibody treatment.
Conclusions: Our data provides new evidence for the function of L1CAM and its soluble form in promoting
cancer cell adhesion to ECM and cell migration. Thus, L1CAM is validated further to be a potential early diagnostic
marker in breast cancer progression and a target for breast cancer therapy.
Background
Cell adhesion and migration are fundamental processes
that occur during organogenesis, neural development,
tissue regeneration and immune response, all of which
require communication between cells and interaction of
cells with their microenvironment. These two processes
are also critical for tumor cells traveling to distant sites
during metastasis [1,2]. Recent studies on molecules
involved in cancer metastasis have found that several
neural cell recognition molecules are abnormally
expressed and functioning in clinical patient samples
and in in vitro tumor models [3-5]. Surface proteins,
such as N-CAM [6,7], Ng-CAM [8], L1CAM [9,10] and
neogenin [11], which predominantly exert effects in
nervous system development, have been demonstrated
also to facilitate tumor cell progression in certain types
of cancer.
L1CAM (CD171) is the initial member of the L1
family of immunoglobulin superfamily proteins and has
pivotal roles in mediating the correct formation of neu-
ronal connections during embryo neurogenesis [12-14].
L1 and its homologous cell adhesion molecules are dis-
tributed mainly in the central and peripheral nervous
systems. With six Ig-like and five fibronectin type III
(FN III) domains in the extracellular region and a con-
served intracellular cytoplasmic tail, this transmembrane
glycoprotein possess sufficient functioning domains to
interact with guiding cues or extracellular matrix pro-
teins. Such interactions of neurons with their immediate
environment instruct cell and/or axonal movement [15].
L1CAM performs important functions in neuron-neuron
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ciculation, axon outgrowth and synaptic plasticity
[5,13,15-17]. The importance of L1CAM in the nervous
system can be emphasized by the severe syndromes that
result from various L1 gene mutations categorized as
L1-syndrome [12,13,18-20]. One of the most severe
results of this syndrome is hydrocephalus, which in
many cases is due to mutations causing production of
truncated L1 ectodomain, which is secreted. On the
other hand, Kalus et al. [21] found that L1-dependent
neurite outgrowth requires highly regulated proteolysis
of L1 at the cell surface. Otherwise the cellular microen-
vironment would be unfavorable for axon outgrowth.
These findings shed some light on the potential role of
L1 proteolytic cleavage and release of soluble L1 in facil-
itating neuron migration and axon growth cone protru-
sion in the nervous system.
Normally, non-neuronal expression of L1 can be
found only in Schwann cells in the peripheral nervous
system, in some lymphocytes and in part of the renal
system [22,23]. But recent studies unveiled L1CAM’s
abnormal presence in glioma, melanoma, ovarian, colon
and pancreatic cancers [4,10,24,25]. According to these
studies, tumor cells tend to use the same mechanism
involving L1 as neurons do in brain development to
possess an increased migratory ability. Proteolysis of L1,
however, is not tightly regulated as it is in the nervous
system, and is constitutive. The abnormal expression of
L1 in cancerous tissues compared to the normal tissues
suggests its potential as a marker for tumorigenesis.
Soluble L1 resulting from ADAM10 cleavage has been
found in serum and ascites fluid from patients with
ovarian carcinoma or endometriosis [26-28]. This pro-
teolyzed form is proposed either to cis-interact with
integrin avb3, avb5 [29] on the cell surface, or to
become integrated into the immediate extracellular
matrix [30]. Studies from other research groups [27,31]
and ours [32] have shown that in colon cancer and
glioma models, L1CAM expression and proteolysis can
be detected at the invasive front of cell cultures, indicat-
ing the role of L1 shedding in the pioneering stage of
cancer cell migration. Expression and cleavage of L1 in
breast cancer cells can be detected both directly from
the cell surface and from secretory vesicles [9,30].
Whether this soluble form can facilitate breast cancer
cell migration or have any roles in other steps of metas-
tasis is still unclear.
In view of previous studies, our current work aims at
elucidating the function of L1CAM, especially its soluble
form, in breast cancer cell migratory processes. From
established datasets on clinical samples of breast cancer,
L1 is found to be among the top ranking of genes
whose expression is up-regulated, and expression is high
in cells with active migration ability in vitro.O v e r
expression of L1 ectodomain alone is adequate to
increase cell adhesion to ECM and increase transmigra-
tion, and this effect can be blocked with anti-L1CAM
antibody. We provide novel evidence to show the solu-
ble form of L1 can be a chemotactic signal to direct cell
migration. These results further emphasize the potential
of L1CAM to be a target for breast cancer treatment.
Results
L1CAM expression level increases with breast cancer cell
progression
Based on the size and invasiveness of tumors, cancer can
be categorized into several advancing stages. To deter-
mine whether L1CAM expression level is correlated with
breast cancer progression, we used Oncomine (http://
www.oncomine.org) to examine microarray results
obtained by Boersma et al. [33] on patients with different
stages of breast cancer. As shown in Figure 1A, COPA
outlier analysis on mRNA levels of 12,427 measured
genes from 95 samples identified L1CAM among the top
2% genes that are over-expressed, ranking it 125 at 75th
percentile and 164 at the 90th percentile threshold. Also,
the percentage of patients with high level L1CAM
expression was shown to increase with the advance of
cancer progression. In our work here, analysis of L1CAM
expression in three breast cancer cell lines, MDA-MB-
435, MDA-MB-231 and MDA-MB-468, revealed that
MDA-MB-468 cells showed relatively low L1CAM
expression both at mRNA and protein levels compared
to the other two (Figure 1C). Consistent with results of
others [34], MDA-MB-468 also was the less migratory
cell line in our transmigration assay (Figure 1B).
Cellular localization of L1CAM by confocal micro-
scopy was apparent on the cell surface, especially at
cell-cell contacts in MDA-MB-231 cells after live immu-
nostaining analysis (Figure 1D). Whereas, distributed
punctate stained vesicles were observed in the cytoplasm
of fixed cells. MDA-MB-468 cells showed low L1CAM
expression in both cases.
Detection and activation of L1 shedding in breast cancer
cells
The 200-220 kDa cell surface L1CAM protein can be
cleaved by plasmin in the third FNIII domain, releasing
140 kDa and 80 kDa fragments [35]. It also can be pro-
teolyzed by ADAM10 at the membrane proximal end of
the extracellular domain into a soluble fragment of
approximately 180-200 kDa and a remaining membrane
bound fragment of about 30 kDa, which could be
further degraded by g-secretase [21]. We examined L1
cleavage in our cells first by probing the whole cell
lysates with antibody NCAM-L1(C-20) against the C-
terminus of the encoded protein. The full-length (200-
220 kDa), ectodomain fragment (180 kDa) and
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MDA-MB-435 and MDA-MB-231 cells (Figure. 2A).
MDA-MB-468 cell lysates showed a very low level of L1
protein expression overall. This suggested that our
breast cancer cells proteolyzed L1CAM via ADAM10 to
release the large ectodomain fragment. We then checked
for the presence of soluble L1 in cell culture medium by
TCA precipitation. Phorbol ester (PMA) stimulation was
reported to increase L1 shedding by ADAM10 [9,30]. As
seen in Figure 2B, PMA treatment resulted in a signifi-
cant increase of soluble L1 (sL1) at 180 kDa in the cul-
ture medium compared to samples prior to treatment.
Even in MDA-MB-468 cell culture supernatant, a clear
band of sL1 could be detected after treatment. However,
no apparent changes occurred in the amount of total
L1CAM in PMA activated cell pellets, indicating this
PMA treatment only activated L1 proteolysis but did
not affect overall L1 protein expression levels.
Over-expressing L1-ectodomain in MDA-MB-468 cells
promoted cell adhesion and migration, but not invasion
To investigate whether the higher migratory ability of
MDA-MB-231 cells compared to MDA-MB-468 (Figure
1B) was due to a higher level of L1 expression and
shedding, we established a stable cell line MDA-MB-468
cells over-expressing the L1 ectodomain (MDA-MB-
468-L1ED) by lentiviral vector infection (Figure 3A). As
shown in Figure 3B and 3C, the infected 468-L1ED cells
successfully displayed a high level of L1 protein expres-
sion as detected by UJ127 antibody using FACS analysis
(Figure 3B), and the over-expressed soluble L1ED was
released into the cell culture medium as confirmed by
western blot analysis (Figure 3C).
We then tested any change of cell adhesion and trans-
migration ability in the new stable MDA-MB-468 cell
line over-expressing L1ED. In short, L1ED over-expres-
sion promoted cell adhesion to fibronectin and Matri-
gel™. Shown in Figure 4A, after 45 min incubation,
compared with plain MDA-MB-468 cells and those
infected with empty vector as control, MDA-468-L1ED
cells resulted in a significant increase in adhesion of
about 20% to fibronectin and 15% to Matrigel™. Simi-
larly in the transmigration assay, almost two fold more
cells migrated to the underside of transwell inserts
coated with fibronectin or laminin for MDA-MB-468-
L1ED cells, while the control vector infected cells
showed the same migration rate as uninfected MDA-
MB-468 cells (Figure 4B). However, no significant
Figure 1 Characterization of L1CAM expression in human breast cancer. (A) ONCOMINE gene microarray database was explored for L1CAM
gene expression in breast cancer and the results of Boersma et al. [33] were displayed by different stages. COPA analysis yielded a score at 1.95,
ranking L1CAM 125
th at 75% outlier among 12,427 measured genes on mRNA level (http://www.oncomine.org/). (B) Quantitative analysis of
transmigration assay between MDA-MB-231 and MDA-MB-468 cells. Each cell suspension (10
5 cells) was plated into the upper chamber of
Transwell inserts precoated with LN on the underside, and allowed to migrate for 12 h at 37°C. Cells that migrated to the backside of the insert
were stained with crystal violet and counted from five random views. Data are mean ± SEM of three independent experiments. **, p < 0.01. (C)
L1CAM expression level examined by RT-PCR and western blot analysis in MDA-MB-435, MDA-MB-231 and MDA-MB-468 cells. Beta-actin and b-
tubulin were internal controls for each assay respectively. DNA band markers and protein molecular weight markers are shown as indicated. (D)
Immunostaining of L1CAM in MDA-MB-231 and MDA-MB-468 cells observed by confocal microscopy. Fixed and permeablized staining with
polyclonal antibody NCAM-L1 (C-20) (upper panel) or live staining with monoclonal antibody UJ127 for L1CAM (lower panel) are shown in red.
Nuclei stained with bisbenzimide are shown as blue.
Li and Galileo Cancer Cell International 2010, 10:34
http://www.cancerci.com/content/10/1/34
Page 3 of 12difference was observed for MDA-MB-468-L1ED cells in
the invasion assay with transwell inserts coated on top
with Matrigel™ (Figure 4C).
Attenuating L1 expression in MDA-MB-231 cells
decreased adhesion and transmigration
With the above findings that soluble L1 facilitates cell
adhesion and migration, we then tested the effect of
attenuating L1 expression by shRNA on breast cancer
cell motility. A commercially available shRNA vector
targeting L1 was used previously by our group [36].
Here, the attenuating effect of L1-shRNA in MDA-MB-
231 cells was shown by RT-PCR and western blot in
Figure 5A and 5B. Though slightly detectable L1
remained, over 90% of L1CAM was knocked down after
shRNA interference. As seen in Figure 5C, a significant
decrease (12% less) of cell adhesion to laminin was
obtained for MDA-MB-231 cells infected with L1-
shRNA compared to the control infected or uninfected
cells. A dramatic (30%) drop also was detected in the
number of transmigrated cells for MDA-MB-231-
L1shRNA in the transmigration assay onto laminin (Fig-
ure 5D). A less dramatic but significant drop in transmi-
gration (16%) occurred onto fibronectin.
Antibody blocking reduced L1-dependent cell adhesion
and directional migration
Monoclonal antibody (mAb) blocking has been reported
as an efficient treatment for targeting specific proteins
[24,37]. Here, we used two mAbs against different
Figure 2 L1 proteolysis in breast cancer cell lines. (A) Western blot analysis of L1CAM expression in MDA-MB-231, MDA-MB-435 and MDA-
MB-468 cells. 30 μg extracts from each cell line were probed with NCAM-L1 (C-20) for L1. A fragment around 30 kDa after cleavage is shown
(arrow) in MDA-MB-435 and MDA-MB-231 cell extracts. (B) Activation of L1 shedding by PMA. Confluent cells after one day in culture were
incubated at 37°C for 1 hr with or without 100 ng/mL PMA. Cell culture supernatants were then collected and TCA precipitated, and cell pellets
were lysed respectively. Monoclonal antibody UJ127 was used to probe L1 in all samples. NC, plain QT6 cells as negative control. PC1 and PC2,
glioma cell lines U-87 MG and T98G as positive controls.
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L1 in cell adhesion and motility assays. Compared to
isotype IgG treatment, MDA-MB-231 cells blocked by
L1 antibodies had significantly decreased binding ability
to fibronectin (by 17%, Figure 6A) and to diluted Matri-
gel™ (by 25%, Figure 6B). Thus, monoclonal antibodies
5G3 and UJ127, which target different extracellular
domains of L1, displayed almost no difference in their
ability to block cell adhesion of MDA-MB-231 cells.
Purified L1-Fc has been reported as an adhesion sub-
strate for ovarian cancer cells and attractant for endothe-
lial cell migration [38]. We used conditioned culture
medium from L1ED over-expressing cells to evaluate
whether sL1 can direct breast cancer transmigration in
our model. Shown in Figure 6C, conditioned medium col-
lected from both L1ED over-expressing (468-L1) and
PMA activated (468 + PMA) cells attracted significantly
more MDA-MB-468 cells to transmigrate onto laminin, as
compared to plain (468) medium. This chemoattractant
effect could be totally neutralized by adding mAb 5G3
against the L1ED (Figure 6C), while no decrease was
observed with IgG control. Thus, this demonstrates that
the L1ED can induce directional movement of breast can-
cer cells in our transmigration assay.
Discussion
From a neural recognition molecule in brain develop-
ment to a potential marker in cancer progression, this
Figure 3 Over-expressing L1-ectodomain in MDA-MB-468 cells. (A) Schematic diagram of Lvv 1879 vector containing L1ED. 3350 bp L1
ectodomain fragment was amplified and inserted into Lvv 1879 via SpeI and XhoI restriction enzyme sites. The constructed lentivirus was used
to infect MDA-MB-468 cells to establish a new stable cell line. (B) Immunostaining and FACS analysis of L1CAM level in MDA-MB-468-L1ED
compared to mock vector infected and plain MDA-MB-468 cells. (C) TCA precipitation and western blotting examining over-expressed L1
ectodomain release in MDA-MB-468-L1ED culture medium by monoclonal antibody 5G3. The amount of cell associated L1 in pellets was probed
by polyclonal antibody NCAM-L1 (C-20).
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eral cancer types [4,39]. We analyzed previously gener-
ated datasets of clinical samples and found that L1
expression levels were correlated with breast cancer
stage progression and also were higher in more meta-
static breast cancer cell lines that we used for our
experiments here. We present new insights into how
soluble L1 facilitates breast cancer cell motility by
demonstrating that ectopic L1ED expression increased
cell adhesion and migration in less migratory cell lines.
In addition, we displayed a new function of shed L1 as
an extracellular attractant in cancer cell migration.
Molecular profiling has been a great aid in sorting out
potential markers for early cancer diagnosis. From pre-
viously established databases of breast cancer clinical
samples or in vitro cultured cell lines, the L1CAM gene
or the region in the X chromosome where it is located
(Xq28) [40,41] has been found to be abnormally ampli-
fied in some cases [33,42,43]. Its over-expression also is
correlated with progressing stages of cancer in patients
(Figure 1A, [33]). Results from analysis of our cultured
cell lines revealed a similar trend (Figure 1B and 1C),
with the less migratory MDA-MB-468 cells expressing
the lowest level of L1CAM protein. Our laboratory also
found L1 is expressed in invasive and metastatic
SUM149 breast cancer cell line (data not shown) and
o t h e r sh a v es h o w nL 1e x p r e s s i o ni nM D A - M B - 2 3 1a n d
-435 cells as well [9]. Though the mechanism of how L1
is upregulated in metastatic tumors is still undefined, it
is coincidently upregulated with ADAM10 as target
genes of b-catenin/TCF signaling, with co-expression at
the invasive front of colon carcinomas [44]. Effects of
various growth factors in cancer tissues [45] also may
contribute to the abnormal presence of L1CAM. Inter-
estingly, analysis of 145 primary breast tumors and 51
breast cancer cell lines (including MDA-MB-231) in
another study [46] did not show that the expression of
L1CAM was correlated with genome copy number, sug-
gesting that expression was not due to genomic aberra-
tions (e.g. amplification). However, they did not give L1
expression results for individual cell lines. We believe
L1 promotes breast cancer progression by its
Figure 4 Increased L1ED expression promotes cell adhesion and transmigration. (A) Plain MDA-MB-468, mock vector- or L1ED-infected
cells were seeded into 96-well plates pre-coated with Matrigel™ (grey bar) at 20 μg/mL or fibronectin (black bar) at 10 μg/ml for the cell
adhesion assay as described. (B) Cell transmigration assay using different MDA-MB-468 cell types. Shown are representative undersides of
membranes stained with crystal violet after transmigration towards fibronectin. Quantitative analysis of cells migrated to the underside of the
inserts is summarized in the lower panel. Data are mean ± SEM of three independent experiments, each with triplicate sets. * and #, P < 0.05, vs.
mock vector. (C) Cell invasion analysis on Matrigel™ transwell inserts coated on the top side.
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A D A M 1 0t or e l e a s et h es o l u b l eL 1 E D ,w h i c ht h e n
exerts its autocrine/paracrine stimulatory effect.
L1 functions in the developing nervous system mostly
as a cell surface adhesion/recognition protein by homo-
philic binding and heterophilic interaction with ECM
and other migration guiding cues [15]. It can become
endocytosed and can activate the intracellular MAP
kinase pathway [47-49] to elicit its effects. Regulated
proteolysis has been detected in developing mouse brain
[9]. However, the presence of unregulated levels of solu-
ble L1ED during nervous system development causes
severe forms of L1 syndrome [12,13,18-20], and consti-
tutive L1 shedding can favor cell migration from tumors
[3,28]. Gutwein and colleagues [30] have reported that
in the AR breast cancer cell line, L1 cleavage by
ADAM10 can be detected to occur both in minute vesi-
cles termed exosomes and at the cell surface to be
released into the culture medium. These two forms of
cleaved L1 both can be considered to be forms of solu-
ble L1 (sL1). Our analysis corroborated their study on
L1CAM localization in intracellular vesicles and cleavage
at the membrane-proximal end in different breast can-
cer cell lines. Although Mechtersheimer et al. [9] found
only a slightly detectable band at around 30 kDa to sug-
gest L1 proteolysis in MDA-MB-231 and MDA-MB-435
cells in their study, this difference could be a result of
different antibodies being used or different culture con-
ditions. Alternatively, the cytoplasmic domain already
may have been degraded (presumably by g-secretase),
which sometimes occurred in our breast cancer cell
lines as well (data not shown). Consistent with this idea
is that they were able to clearly demonstrate soluble
L1ED in the cell culture supernatant from those cell
lines [9].
sL1 thus generated has been reported in various can-
cers to be an active factor in angiogenesis [38], anti-
apoptosis [50] and cell migration [36]. The mechanisms
proposed for sL1 working in tumors can be categorized
based on to which part a receptor would primarily bind.
With an RGD motif on its sixth Ig domain, the sL1
retains similar roles as cell-surface L1 and still can
recruit and bind to integrins such as avb3, avb5, and
avb3 [9,29] to activate FAK and Src at focal adhesion
complexes. The signal transduction initiated thereafter
can stimulate cytoskeleton protein reassembly to gener-
ate directional membrane protrusions. On the other
hand, sL1 also can be integrated into the immediate
extracellular matrix [51] by binding to laminin or pro-
teoglycan as a chemoattractant for any following cells to
attach and adhere. Either way, sL1 provides flexible con-
nections with the ECM for cells to mobilize [52]. Since
cell migration speed potentially depends on the turnover
rates of adhesion and de-adhesion cycles [53], fast and
Figure 5 Attenuating L1CAM in MDA-MB-231 decreases cell adhesion and migration. Efficiency of L1CAM-shRNA to knock down L1
expression in MDA-MB-231 cells was examined by rtPCR (A) and western blot (B). (C) Analysis of cell adhesion after L1-shRNA infection. Assays
were done as previously described. (D) Cell transmigration assay was done as described previously on laminin- or fibronectin-coated transwell
inserts. Results shown are mean ± SEM of three independent experiments with triplicates. **, P < 0.01 vs MDA-MB-231 cells infected with control
vector.
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naling actually facilitate the event of cell movement
[54]. Our results obtained by overexpressing sL1 in
MDA-MB-468 cells supported such a mechanism (Fig-
ures 3 and 4). Specifically, ectopic L1ED expression
alone is sufficient to cause more cells to adhere to
matrix and then to migrate. However, no significant
change was observed in the Matrigel™ cell invasion
assay. This suggests that soluble L1 serves mostly as a
released factor to allow adhesion and exploration of the
cell’s immediate environment. In order to invade
through the ECM, gene expression changes causing pro-
teolysis and degradation of the matrix are required
[54,55], which evidently are not achieved by adding sL1
alone in a short time period.
Given that L1CAM is rarely present other than in the
nervous system, immune effector cells, and kidney
under normal circumstances [23,41], its constitutive
expression and shedding in tumors makes it an ideal
marker for cancer detection and treatment. For example,
short hairpin RNA targeting L1CAM, which has been
found to impair axon outgrowth [56] in normal neurons,
can disrupt cell proliferation and neurosphere formation
of brain tumor cells [57]. Our lab has found that attenu-
ating L1CAM by this method in glioma cells decreased
focal complex turnover, reduced cell motility in vitro,
and halted brain invasiveness in vivo [32]. Here, we
showed that shRNA targeting L1 in breast cancer cells
can weaken cell adhesion and transmigration ability to a
significant extent. Also, antibodies blocking L1, which
have been used by others [24] and us [32,58] to inhibit
cancer cell growth and motility, were shown to reduce
breast cancer cell adhesion and migration in our assay.
These results point to L1CAM as being an over-
expressed cell surface molecule in tumors and that it
contributes importantly to cell migratory behavior.
PMA is reported to elevate L1 shedding by activating
the PKC pathway [59]. In our experiments, PMA treat-
ment increased sL1 in the culture medium, whereas the
overall L1 protein expression level remained unchanged.
Figure 6 Inhibition of cell adhesion and directional transmigration by L1CAM antibodies. MDA-MB-231 cells pre-treated with control
isotype IgG or either of the two anti-L1CAM monoclonal antibodies targeting its ectodomain (5G3 or UJ127) were added into 96-well plates
coated with fibronectin (A) or Matrigel™ (B) for adhesion assay as described before. The antibody was also present during the incubation time.
(C) Conditioned medium with 0.5% BGS from each cell culture system shown on X-axis was collected and added into the lower chamber as
chemoattractant in transmigration assay. Where indicated, L1CAM antibody 5G3 or isotype IgG were added at 2 μg/mL in the lower chamber.
MDA-MB-468 cells were seeded in serum free medium in the top and allowed to migrate for 12 hours. Migrant cells to the underside were
stained and counted for 5 random fields to obtain the average. *, p < 0.05 vs. conditioned medium from MDA-MB-468; #, p < 0.05 vs. treatment
with control antibody.
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upon addition of PMA initiated gene expression [60,61],
but did not increase L1CAM expression directly.
Whereas, the expression level of ADAM10 or another
protease involved in ADAM maturation [62] may be
promoted, so that more surface L1, together with other
protein substrates, would be cleaved. For the same rea-
son, more MDA-MB-468 cells migrated toward condi-
tioned medium from PMA activated cells. In that
analysis, it is hypothesized that soluble L1 in condi-
tioned medium might have bound to the coating matrix
like integrated tracks in the ECM, attracting the cells to
migrate and/or L1 could have exerted its effects in its
soluble form. Additionally, homophilically-bound L1
fragments might have caused integrin recruitment on
cell protrusions to form focal complexes and speed up
the overall motility [53]. The reason why supernatant
from PMA-activated cells is more attractive than super-
natant from 468-L1ED cells could be because more
active cell responses were initiated via the PKC pathway
stimulated by PMA. Nonetheless, the dramatic increase
in transmigration could be totally reversed by addition
of anti-L1CAM antibody (Figure 6C), demonstrating
that the attractant was the L1ED.
Conclusions
Overall, our present study demonstrates a positive cor-
relation of L1 expression level with breast cancer cell
migratory ability. The role of L1CAM and its soluble
form was shown to facilitate cell adhesion to ECM and
transmigration ability by experimentally increasing the
soluble L1ED as well as attenuating L1 protein levels.
sL1 also was shown to be an attractant for directional
breast cancer cell migration. These effects of over
expression of the L1ED in low migratory breast cancer
cells (MDA-MB-468) parallel the role of L1 in early
brain development, however in an unregulated manner.
Consequently, abnormal L1CAM expression may be a
good marker for detection of breast cancer progression
and metastatic potential.
Methods
Cell culture conditions
Human breast cancer cell lines MDA-MB-231, MDA-
MB-435 and MDA-MB-468 were used. MDA-MB-231
(ATCC No. HTB-26) was a gift from Dr. Ulhas Naik
(Univ. of Delaware), MDA-MB-435 cell line was gifted
by Dr. Danny Welch (Univ. of Alabama, Birmingham)
and MDA-MB-468 cells were from Dr. Leslie Krueger
(A.I. DuPont Hospital for Children). These three cell
lines were maintained in DMEM (Mediatech Inc., Hern-
don, VA), supplemented with 10% bovine growth serum
(BGS; Hyclone, Waltham, MA), 100 μg/mL penicillin/
streptomycin (Mediatech Inc.) and 2 mM L-glutamine
(Mediatech Inc.). Quail fibrosarcoma cell line QT6 cells
were cultured in Medium 199 (Mediatech, Inc.) with 5%
FBS, 20% tryptose phosphate broth, 2 mM L-glutamine
and penicillin-streptomycin. Human glioma cell line
U-87 MG was obtained and kept as described in [36].
All cell lines were cultured at 37°C in a humidified
atmosphere containing 5% CO2.
Antibodies and reagents
Three different antibodies against L1CAM were used.
Polyclonal antibody NCAM-L1 (C-20) (sc-1508, Santa
Cruz Biotechnology, Santa Cruz, CA) recognizes the C-
terminal region of L1CAM protein, monoclonal anti-
body 5G3 (sc-33686, Santa Cruz Biotechnology) recog-
nizes the first Ig domain and UJ127 recognizes the 5
th
fibronectin repeat (GTX23200; Gene Tex, Irvine, CA).
Monoclonal antibody against b-tubulin (Developmental
Studies Hybridoma Bank, Iowa City, Iowa) and mouse
IgG whole molecule (Jackson ImmunoResearch, West
Grove, PA) were used for controls where indicated.
Phorbol 12-myristate 13-acetate (PMA) was purchased
from Sigma (Sigma-Aldrich Corp., St. Louis, MO).
RT-PCR analysis
RNA extraction and generation of first strand cDNA
was carried out using PureLink total RNA purification
system (Invitrogen, Carlsbad, CA) and the SuperScript
III First-Strand Synthesis System (Invitrogen). PCR was
performed using the following primers with the length
for each product indicated in parenthesis:
L1CAM [GeneBank: 3897] sense, 5′-TACCGCTTC-
CAGCTTCAG -3′;
antisense, 5′- TGATGAAGCAGAGGATGAGC -3′
(460bp)
-actin [GeneBank: 60]: sense, 5′- GCTCGTCGTCGA-
CAACGGCTC -3′;
antisense, 5′- CAAACATGATCTGGGTCATCTT
CTC-3′ (353bp).
PCR was carried out as described [32] using Master
Mix (Promega, Madison, WI) in a thermal cycler
(Techne, Burlington, NJ), and products were then elec-
trophoresed on a 1.5% agarose gel and visualized by
ethidium bromide staining.
Vector construction and lentivirus infection
L1 ectodomain (L1ED) fragment was generated from the
pCDNA3-L1 vector kindly provided by Dr. Vance Lem-
mon (The Miami Project to Cure Paralysis, University of
Miami, FL). The following primers with SpeI or XhoI
(NEB, Ipswich, MA) cleavage sites were used to amplify
the sequence: sense, 5′-GAAACTAGTCGCCGG-
GAAAG-3′;a n t i s e n s e ,5 ′- GCCTCGAGGAGGGAGCC-
3′. The resulting 3350bp L1ED was then inserted into a
lentivirus vector (Lvv 1879; provided by Dr. John C.
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CMV promoter. Empty Lvv 1879 vector served as a
negative control. Constructs obtained were both con-
firmed by DNA sequencing and used to make virus to
infect MDA-MB-468 cells. MDA-MB-231 cells were
infected with L1-shRNA vector or the mock control. An
shRNA Lentiviral vector targeting human L1CAM
(TRCN0000063917; cat No. RHS3979-97052304) and
the non-targeting control vector pLKO.1 were pur-
chased from Open Biosystem (Huntsville, AL). All four
vector constructs were then transfected into HEK 293T/
17 respectively, with the helper plasmid pMD.G and
packaging plasmid pCMVΔR8.2 by ratio of 4:3:1 (20 μg:
15 μg: 5 μg for a 10 cm plate) using standard calcium
phosphate method [63]. Supernatants containing viruses
were collected 48 and 72 hours after transfection and
target cells were infected using 10 μg/mL polybrene.
Stable infected cell lines with encoded vectors were
selected by 2 μg/mL puromycin resistance and con-
firmed by immunoblotting or FACS analysis.
Western blot analysis
Protein extraction and western blot analysis was per-
formed as described [36]. In brief, plain MDA-MB-231,
MDA-MB-435 and MDA-MB-468 cells or those stably
infected cell lines were solubilized using RIPA buffer.
Cell lysates were then quantified using the BCA Assay
(Pierce Biotechnology, Pittsburgh, PA). Unless otherwise
indicated, a total of 30 μg target proteins for each sample
were probed with antibodies as indicated in each test.
Immunohistochemistry
Immunofluorescent staining was performed as before
[36] with minor differences. In brief, cells cultured on
coverslips pre-coated with 200 μg/mL poly-L-ornithine
(Sigma-Aldrich, St. Louis, MO) were directly stained with
primary antibodies diluted in PBS with 5% heat-inacti-
vated serum on ice for live staining. Alternatively, cells
were fixed with 1% formaldehyde in PBS followed by pri-
mary antibody diluted in PBS with 5% normal goat
serum and 0.03% Triton-X 100. In either case, the cover-
slips were then rinsed with PBS and incubated with
Alexa Flour 594 secondary antibody (Molecular Probes,
Invitrogen) diluted in PBS with 5% normal goat serum
for 45 min-1 hr at room temperature. After washing,
nuclei were stained in 10 μg/mL bisbenzimide (Sigma-
Aldrich) and mounted. Thus prepared slides were visua-
lized and digital images were taken by using a Zeiss LSM
510 Confocal imaging system (Carl Zeiss, Thornwood,
NY, USA) with appropriate argon beam lasers.
FACS analysis
Cells were trypsinized, fixed (as described above) and
stained with a saturating amount of mAb UJ127 or just
secondary antibody Alexa Fluor-488 (Molecular Probes,
Invitrogen) as control. Stained cells were examined and
analyzed using a FACSCalibur flow cytometer (Becton
Dickinson) using Cell Quest software.
L1 shedding analysis
L1 shedding analysis was performed as described [9]
with minor modifications. In brief, 10
6 cells were cul-
tured in 35 mm tissue culture plates in complete med-
ium for 24 hrs. The next day, culture plates were rinsed
with PBS to remove growth factors and then 1 mL
serum-free DMEM was replaced for an hour while cells
remained normally attached. Where indicated, PMA
(100 ng/mL) was co-incubated with the cells. After 1 hr
incubation at 37°C, culture medium was separated from
cell debris by centrifugation. The culture media were
TCA precipitated and dissolved in LDS loading buffer
(Invitrogen), while the pellets were lysed respectively as
in western blot analysis. Proteins thus obtained were all
subjected to western blotting for the presence of L1
with antibodies as indicated.
Cell adhesion assay
Cell adhesion assays were performed in 96-well flat bot-
tom plates coated with different ECM proteins. Briefly,
50 μL/well solution of either fibronectin (10 μg/mL;
Sigma-Aldrich) or laminin (10 μg/mL; Invitrogen) in
PBS, or Matrigel™ (20 μg/mL; BD) in serum free DMEM
were pre-added to 96-well plates and incubated at 4°C
overnight. The plates were then rinsed and blocked with
0.2% BSA for 2 h at room temperature followed by
three times PBS washing. Cells were then added to each
well in triplicate and incubated for 45 min at 37°C.
After washing, cells remaining attached to the plates
were fixed and stained with a solution containing 0.5%
crystal violet, 2% ethanol and 40% methanol in PBS. 100
μL SDS (1% wt/vol) was added to each well after wash-
ing, and the absorbance of the color substrate was mea-
sured with an FLUOstar OPTIMA microplate reader
(BMG Labtechnologies, Offenburg Germany) at 595 nm.
The percentage of bound cells was calculated by divid-
ing the optical density of the adherent cells by that of
the initial input cells, with BSA-coated wells subtracted
as background reading. Where indicated, mAbs or
mouse IgG negative controls were pre-incubated with
the cells for 30 min at 4°C and then kept present during
the adhesion period.
Cell transmigration and invasion assay
Cell transmigration assays were performed as described
[9] using 8.0 μm pore size Transwell inserts (Costar,
Cambridge, MA) with some modifications. In brief, the
bottom of the insert membrane was coated with either
fibronectin or laminin at 10 μg/mL in PBS at 37°C for
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night (0.5% FBS), harvested with trypsin, washed and
then resuspended in basal DMEM medium without
serum. 10
5 cells in 0.1 mL were then added to the
upper chamber of the inserts, and 0.6 mL DMEM with
10% serum was added to the lower chamber. Where
indicated, conditioned medium obtained as described
[64] from cell culture supernatants was used instead in
the lower chamber. After 12 h at 37°C, cells remaining
on the upper side of the membrane were removed using
cotton swabs, while the cells that migrated to the under-
side were fixed in methanol at room temperature for 30
min and then stained with crystal violet solution. The
number of migrated cells was counted under a micro-
scope in five fields at 100× magnification. Each assay
was done in triplicate and presented as mean ± SEM.
Cell invasion assays were done similarly to transmigra-
tion assays, only instead, transwell inserts were pre-
coated with Matrigel™ at 1 μg/μL on the topside. Cells
were allowed to invade for 24-48 hrs under normal cul-
ture conditions.
Statistical Methods
Data presented are mean ± SEM of at least three
repeats. Student′s t-test was used to analyze difference
between two groups. ANOVA was used when more
than two groups were involved, and then Student’s
t-test was further applied to analyze difference between
groups. * or #, P < 0.05 was considered as significant;
**, P < 0.01.
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